Serpin Pharma LLC has identified serpin peptide derivatives acting as pro-low-density lipoprotein receptor-related protein 1 (LRP-1) agonists reported to be useful for the treatment of acute lung injury, eosinophilic esophagitis, viral infection, and acute and neuropathic pain, among others.
Siteone Therapeutics Inc. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Stanford University researchers are seeking patent protection for a medical device for performing endovascular surgical procedures, such as thrombectomy, rotablation, drug delivery and treating brain aneurysms. The device includes a magnetically actuated untethered rotation device, i.e., a magnetic spinner, that can navigate in blood vessels through its spinning-enabled propulsion.
Tsinghua University has described non-structural protein 3 (nsp3; PL-pro) (SARS-CoV) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Tarapeutics Science Inc. has identified phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors reported to be useful for the treatment of cancer, rheumatoid arthritis, asthma, chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus.
Medshine Discovery Inc. has synthesized mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Researchers from the University of Pittsburgh seek patent protection for a method of treating motor disorders by applying an electrical stimulus to neurons in the thalamus. The invention is based on their discovery that deep brain stimulation of specific lateral areas in the thalamus leads to improvements in motor outputs of voluntary movements affected by motor disorders.